Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment

Open access
Nishimura, Masato, Jung, Eun-Jung, Shah, Maitri Y., Lu, Chunhua, Spizzo, Riccardo, Shimizu, Masayoshi, Han, Hee Dong, Ivan, Cristina, Rossi, Simona, Zhang, Xinna, Nicoloso, Milena S., Wu, Sherry Y., Almeida, Maria Ines, Bottsford-Miller, Justin, Pecot, Chad V., Zand, Behrouz, Matsuo, Koji, Shahzad, Mian M., Jennings, Nicholas B., Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Sood, Anil K., Calin, George A.·2013·Cancer Discovery

Abstract

Development of improved RNA interference–based strategies is of utmost clinical importance. Although siRNA-mediated silencing of EphA2, an ovarian cancer oncogene, results in reduction of tumor growth, we present evidence that additional inhibition of EphA2 by a microRNA (miRNA) further “boosts” its antitumor effects. We identified miR-520d-3p as a tumor suppressor upstream of EphA2, whose expression correlated with favorable outcomes in two independent patient cohorts comprising 647 patients. Restoration of miR-520d-3p prominently decreased EphA2 protein levels, and suppressed tumor growth and migration/invasion both in vitro and in vivo. Dual inhibition of EphA2 in vivo using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes loaded with miR-520d-3p and EphA2 siRNA showed synergistic antitumor efficiency and greater therapeutic efficacy than either monotherapy alone. This synergy is at least in part due to miR-520d-3p targeting EphB2, another Eph receptor. Our data emphasize the feasibility of combined miRNA–siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases. Significance: This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA in nanoliposomal particles to target oncogenic pathways altered in ovarian cancer. Combined targeting of the Eph pathway using EphA2-targeting siRNA and the tumor suppressor miR-520d-3p exhibits remarkable therapeutic synergy and enhanced tumor suppression in vitro and in vivo compared with either monotherapy alone. Cancer Discov; 3(11); 1302–15. ©2013 AACR. See related commentary by Kasinski and Slack, p. 1220 This article is highlighted in the In This Issue feature, p. 1207

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0159

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 160

Metadata

Authors
Nishimura, M., Jung, E.-J., Shah, M. Y., Lu, C., Spizzo, R., Shimizu, M., Han, H. D., Ivan, C., Rossi, S., Zhang, X., Nicoloso, M. S., Wu, S. Y., Almeida, M. I., Bottsford-Miller, J., Pecot, C. V., Zand, B., Matsuo, K., Shahzad, M. M., Jennings, N. B., Rodriguez-Aguayo, C., Lopez-Berestein, G., Sood, A. K., & Calin, G. A.
Venue
Cancer Discovery
Published
2013-11-01
Volume
3
Issue
11
Pages
1302-1315
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2139242035
Cited by
160
References
1
FWCI
5.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0159
The paper
Nishimura, M., Jung, E.-J., Shah, M. Y., Lu, C., Spizzo, R., Shimizu, M., Han, H. D., Ivan, C., Rossi, S., Zhang, X., Nicoloso, M. S., Wu, S. Y., Almeida, M. I., Bottsford-Miller, J., Pecot, C. V., Zand, B., Matsuo, K., Shahzad, M. M., Jennings, N. B., . . . Calin, G. A. (2013). Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0159

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.